Back to results

TerminatedPhase 3

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

NCT03174522

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Fakultní nemocnice Ostrava

Ostrava, Czechia

+14 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2017-04-25
Enrollment: 49 participants
Sponsor: Ixaka Ltd
Purpose: treatment

Locations (15)

Fakultní nemocnice OstravaOstrava, Czechia
Pécsi Tudományegyetem, PTE-KK I. sz Belgyógyászati KlinikaPécs, Hungary
Leids Universitair Medisch CentrumLeiden, Netherlands
Maastricht Universitair Medisch CentrumMaastricht, Netherlands
Hospital Garcia de Orta, EPEAlmada, Portugal
Centro Hospitalar Lisboa Norte, EPELisbon, Portugal
Centro Hospitalar de São JoãoPorto, Portugal
Hospital Universitari Germans Trias i PujolBadalona, Barcelona, Spain
Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Vall d'HebronBarcelona, Spain
Hospital Universitario Puerta del MarCadiz, Spain
First site: Hospital Universitario Reina SofíaCórdoba, Spain
Hospital Regional UniversitarioMálaga, Spain
Hospital General Universitario Morales MeseguerMurcia, Spain
University Hospital of WalesCardiff, United Kingdom

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM — TrialFind